Valuation : Camurus AB

Market Cap 34.93B 3.65B 3.14B 2.96B 2.7B 5.05B 345B 5.07B 13.56B 177B 13.71B 13.41B 570B P/E 2026 *
36.5x
P/E 2027 * 23.7x
Enterprise Value 30.41B 3.18B 2.74B 2.57B 2.35B 4.4B 300B 4.41B 11.8B 154B 11.94B 11.68B 496B EV / Sales 2026 *
10.6x
EV / Sales 2027 * 7.77x
Free-Float
66.89%
Yield 2026 *
-
Yield 2027 * -
1 week-2.04%
Current month+0.67%
1 month-5.22%
3 months+6.64%
6 months+16.44%
Current year-8.03%
1 week 51.75
Extreme 51.75
54.7
1 month 51.75
Extreme 51.75
58.3
3 years 23.66
Extreme 23.66
67.55
5 years 11.16
Extreme 11.16
67.55
Manager TitleAgeSince
Chief Executive Officer 63 01/01/2003
Director of Finance/CFO 57 01/07/2025
Chief Tech/Sci/R&D Officer 58 01/01/2025
Director TitleAgeSince
Director/Board Member 63 01/01/2002
Chairman 77 01/01/2015
Director/Board Member 61 07/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.52%-2.04%-18.99%+113.19% 3.65B
-0.88%-2.15%+58.05%+105.26% 1,024B
-1.15%+2.68%+54.25%+74.19% 663B
-1.44%+0.38%+20.65%+76.13% 453B
-0.95%+0.31%+31.03%+37.89% 352B
-3.18%+2.08%+22.97%+41.96% 304B
+0.25%+0.62%+0.55%+11.20% 252B
-1.55%+1.11%+54.15%+75.59% 236B
+0.02%+2.24%-13.83%-55.80% 206B
-0.15%+3.65%+31.24%+103.39% 187B
Average -0.98%+1.26%+24.01%+58.30% 408.71B
Weighted average by Cap. -1.04%+0.62%+37.64%+66.99%

Financials

2026 *2027 *
Net sales 2.86B 299M 257M 242M 221M 413M 28.19B 414M 1.11B 14.46B 1.12B 1.1B 46.6B 3.75B 392M 337M 317M 290M 542M 36.99B 543M 1.45B 18.98B 1.47B 1.44B 61.14B
Net income 949M 99.2M 85.36M 80.32M 73.37M 137M 9.37B 138M 368M 4.81B 373M 364M 15.48B 1.45B 152M 131M 123M 112M 210M 14.33B 211M 564M 7.35B 570M 558M 23.69B
Net Debt -4.52B -472M -406M -382M -349M -653M -44.58B -655M -1.75B -22.87B -1.77B -1.73B -73.68B -5.81B -607M -522M -491M -449M -840M -57.31B -842M -2.25B -29.4B -2.28B -2.23B -94.73B
Logo Camurus AB
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Employees
-
Date Price Change
07/09/26 51.80 -1.71%
04/09/26 €52.70 -2.32%
03/09/26 €53.95 +1.51%
02/09/26 €53.15 +0.66%
01/09/26 €52.80 +0.86%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
587.00SEK
Average target price
793.00SEK
Spread / Average Target
+35.09%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!